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CHAPTER 1 
 
INTRODUCTION 
 
Autism and the Broader Phenotype  
In 1943 Leo Kanner published a series of case reports that detailed his 
observations of eleven children presenting with what he called, infantile autism.  He 
distinguished these children as distinct from individuals with mental retardation on the 
basis of the lack of social reciprocity they displayed.  Most of the eleven children he 
characterized were males, in fact, only three were females.1  Kanner was first to publish 
features characteristic of the autism phenotype.  His research laid the ground-work for 
further study, assessment and diagnosis of the autism phenotype.    
Autism (OMIM #209850) is now recognized as a formal disorder and is 
characterized as part of a group of developmental disorders called Pervasive 
Developmental Disorders (PDDs), as  classified by the Diagnostic and Statistical Manual 
of Mental Disorders (DSM-IV).  This disorder is distinguished from other PDDs, such as 
Rett Syndrome, Asperger Syndrome and PDD-Not-Otherwise-Specified (PDD-NOS), on 
the basis of diagnostic criteria and assessment measures as outlined by the DSM-IV, the 
Autism Diagnostic Interview and its revision (ADI, ADI-R)2, 3 and the Autism Diagnostic 
Observation Schedule (ADOS).4  Autism is characterized by impairments in three main 
areas: development and use of language, reciprocal social interaction and repetitive 
behaviors, restricted interests and resistance to change in the environment or in daily 
routines.5  Autism represents a continuum of behavioral abnormalities and is more 
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accurately defined as a spectrum of disorders (Autism Spectrum Disorders, ASDs), with 
classic autism representing the more severe end of the spectrum where individuals meet  
diagnostic criteria defined by levels of impairment in the triad of symptom domains 
associated with the disorder.  The presentation of impairments in individuals with autism 
is highly variable.  Additional behavioral complications such as irritability, aggression, 
anxiety, hyperactivity and compulsive behavior may be present and the manifestation of 
impairments changes as a function of time.6  Further, cognitive impairments exist in more 
than two thirds of affected individuals.7  One study found a mental retardation rate of 
66.7%  in individuals with more narrowly defined autism.8  In addition, gastrointestinal 
disturbances such as diarrhea, abdominal pain and/or constipation are frequently present 
in individuals with autism.9  Seizures are a frequent co-morbid condition in autism; 
various studies have found the frequency of epilepsy in autism to be anywhere from 5% - 
38.3% (reviewed in reference 10).10   
 
Prevalence and Heritability of Autism 
The current estimated prevalence of classic autism is 1/500, which increases to 
1/150 (PMID: 17287715) when all PDDs (not Rett Syndrome) are included.7, 8  Males are 
affected four times as frequently as females.8  Twin studies lend strong support for 
genetic determinants in autism: monozygotic twins have a concordance rate of 60% for 
classic autism and up to 92% when broader criteria are used, as compared to dizygotic 
twin concordance rates of 0% and 10% for classic autism and more broadly defined 
impairments, respectively.11, 12  In addition, sibling recurrence rates are estimated to be 
~6-8% when stoppage rules (when the parents of a child with autism decide not to have 
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any more children) are taken into consideration.13, 14  This rate is much greater than 
would be expected based strictly on the population prevalence of autism, which is 1/500 
for narrowly defined autism.  It has been estimated that there are likely 15 or more 
genetic loci that contribute to risk for autism.15  Thus, it seems that the mode of 
inheritance is likely oligogenic with different families possessing different sets of risk 
alleles,5 thus contributing to the range of phenotypes seen within autism.  
 
Serotonin in Autism 
Serotonergic dysregulation has long been suspected to play a role in autism.  In 
1961 Schain and Freedman discovered about one-third of individuals with autism have 
elevated blood platelet serotonin levels (hyperserotonemia)16 and this finding has been 
replicated by other groups.17  In addition, selective serotonin reuptake inhibitors (SSRIs) 
are frequently effective in the treating of ritualized, repetitive behaviors, stereotypies, 
anger, and anxiety associated with autism.18-20  Further, when the essential precursor of 
serotonin (tryptophan) is depleted, autistic symptoms in affected individuals worsen.21  In 
addition, a positron emission tomography (PET) study performed on a cohort of boys 
with autism revealed a decrease in serotonin synthesis in the left thalamus and left frontal 
cortex in five of the seven autistic boys studied and in the right thalamus and right frontal 
cortex of the other two boys (the one female with autism did not have these 
asymmetries).22  PET studies also reveal a developmental difference in the capacity for 
serotonin synthesis between affected and unaffected individuals.6, 23  In a normal 
individual, serotonin synthesis in the brain is equal to or greater than 200% that of adult 
synthesis up until approximately five years of age, and then levels begin to decline 
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gradually until reaching adult levels.6, 23  In individuals with autism, serotonin synthesis 
gradually rises from age two until approximately age fifteen at which point it levels off at 
150% that of normal adult values. 21   Thus some individuals with autism from the age of 
two until five (and likely under two) have less capacity for central nervous system 
serotonin synthesis than children without autism.   
These studies indicate a role for serotonin in autism, but the argument could be 
made that serotonergic dysregulation is secondary to autism rather than etiological. 
Therefore studies looking at serotonin levels in unaffected first degree relatives are 
advantageous.  One study found a positive correlation between serotonin levels in 
subjects with autism and their unaffected first-degree relatives.24  Further, affected 
individuals with an affected sibling have greater serotonin levels than those without an 
affected sibling.25  In addition, rat pups injected with a serotonin analog during 
development exhibit behavioral and neurochemical features reminiscent of autism.26 The 
investigator of this study hypothesizes that elevated blood serotonin levels will lead to a 
decrease in the brain serotonin neurocircuitry by activating negative serotonergic 
feedback loops prematurely.26  This would lead to the decreased serotonin neurocircuitry 
found in the brains of individuals with autism.  Further, in consideration of findings of 
hyperserotonemia in ~25% of individuals with autism, it may be noted that higher levels 
of serotonin in blood platelets may, conceptually, be considered as equal to lower 
amounts of serotonin signaling in the brain since more is being retained within the 
neuron.  These studies are supportive of the idea that serotonin dysregulation is 
etiological rather than secondary to autism. Therefore any genes whose protein products 
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play a role in serotonergic signaling are functional candidate genes for autism 
susceptibility.     
 
Genetic Studies of Autism 
To study genetic determinants of autism risk, several groups have employed 
genome-wide linkage screens using multiplex families to detect regions of the genome 
that tend to be inherited in the affected offspring, and/or utilized allelic association tests 
to determine if common alleles at a given locus confer increased risk for autism.  
Genome-wide linkage screens based on categorical phenotypes within autism have 
revealed significant linkage peaks at chromosomal regions 7q, 2q and 17q.15, 27-42 Follow-
up studies for the 17q region with independent samples demonstrated significant linkage 
at or close to the serotonin transporter (SERT) gene (SLC6A4), located at 17q11.2.38, 43  
 
SLC6A4 as a Functional Candidate Gene 
The SLC6A4 gene is a functional candidate gene in autism as its protein product, 
SERT, is a key regulator of serotonin levels in the presynaptic neuron terminals and post-
synaptic synapses of serotonergic neurons which project from the raphe nuclei of the 
brainstem to cortical areas (reviewed by Purselle and Nemeroff, 2003).44  In addition, 
SERT is expressed on thalamocortical neurons for a short period during development.45  
Further, SERT is expressed in blood platelets where serotonin is taken up and stored in 
dense granules for later release in hemostasis (reviewed by Horiuchi, 2006).46  SLC6A4 is 
a member of the SLC6A gene family of Na+ and Cl- coupled transporters and is most 
similar to the norepinephrine transporter (NET) and dopamine transporter (DAT).47  
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SLC6A4 is expressed from a single gene that undergoes no alternative splicing of its 
coding exons thus the translated 630 amino acid SERT protein expressed in the brain is 
identical to that expressed in the periphery in blood platelets and lymphocytes.47-49  More 
than twenty polymorphisms in the coding region have been identified in SLC6A4.  SERT 
has twelve transmembrane-spanning domains48 with intracellular NH2 and COOH 
termini.50-52 Further, SERT is rapidly modulated by protein kinase G (PKG) and p38 
mitogen-activated protein kinase (MAPK) pathways in addition to various G-protein 
coupled receptors.47, 53-57 Internalization of SERT can be mediated by activation of 
protein kinase C (PKC) pathways, and this is dependent on extracellular serotonin 
levels.54   
 
Increased Linkage at 17q11.2 Based on Sex and Phenotype 
Importantly, the strength of genetic linkage to 17q11.2 is dependant on sex and 
phenotype.39, 58  Our lab did a study of 137 multiplex families that revealed a multipoint 
heterogeneity logarithm of the odds (HLOD) score of 2.74 which increased to 3.62 in a  
subset of families that display comparatively more severe rigid-compulsive behaviors.39  
A further study of 341 multiplex families revealed that when families with affected males 
only (MO; n=202) were analyzed independently of families with at least one affected 
female (female-containing, FC), the peak recessive HLOD score at chromosome 17q11.2 
went from 5.8 to 8.0, with little contribution from the female-containing families.58  An 
HLOD score of 8.0 for a complex psychiatric disorder is striking.  In Cystic Fibrosis, 
there is some allelic heterogeneity, but there is a single, more prominent mutation, 
∆F508, that only has an HLOD score of 6.0.59 
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Figure 1.  Linkage of autism at 17q11.2 is predominantly driven by male-only 
families.  Recessive multipoint HLOD scores are plotted along chromosome 17 as a 
position of the marker in centimorgans (cM) for the pooled autism dataset (All; n=341; 
black line), families in which only males are affected with autism (MO; n=202; blue 
line), and families in which at least one female is affected with autism (FC; n=138; red 
line).  Peak HLOD score for the pooled dataset is 5.8 and increases to 8.0 in MO 
families.58  Figure taken from Sutcliffe et al. (2005).58 
 
 
Rare Variants in SLC6A4 
Our lab went on to probe the possibility that rare or novel variants of SLC6A4 in 
contribute to autism susceptibility.  We used allelic discrimination assays to test for the 
presence of known, rare variants in autism families.  We also selected 120 unrelated 
probands who contributed most to the linkage peak at 17q11.2 and screened their 
SLC6A4 promoter and exons for novel variants.58  The Gly56Ala variant was identified in 
multiple affected families, particularly within the linked subgroup, and included three 
homozygous individuals.  Thus in the linked families, Gly56Ala was present with a 
minor allele frequency (MAF) of ~2.3%, whereas a previous study reported a MAF of 
~0.44% in a nonclinical sample.58, 60  In addition, three novel variants were identified in 
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the screen (Ile425Leu, Leu550Val, and Phe465Leu), all of which are coding substitutions 
that occur in transmembrane domains at highly conserved residues.58  
 
 
Figure 2.  Schematic representation of rare variants discovered in SLC6A4 of 
affected families.  Three of the variants are located within transmembrane domains 
(white dots; Ile425Leu, Phe465Leu, Leu550Val) and two are located in the intracellular 
amino and carboxyl terminal regions (black dots; Gly56Ala and Lys605Asn, 
respectively).  Gly56Ala has previously been reported to exhibit a dose-dependent 
increase in basal 5-HT transport activity and to be resistant to PKG- or MAPK- 
stimulated 5-HT uptake.  Ile425Leu occurs at a nucleotide that has also been affected by 
a previously reported polymorphism (Ile425Val) where the minor allele tracks with 
individuals presenting with a complex psychiatric phenotype including OCD and 
Asperger syndrome.  These novel variants on SERT exhibit a gain-of-function 
phenotype.  Figure taken from Sutcliffe et al. (2005).58 
 
Gly56Ala SERT exhibits a dose-dependant increase in basal 5-HT transport 
activity in EBV-transformed lymphocytes and transfected cells with Ala56 homozygous 
cell lines having an ~75% increase compared to Gly56 homozygous cell lines.58  The 
Ala56 SERT is also refractory to serotonin uptake stimulation induced by acute 
application of PKG or p38 MAPK activators.47, 58  Ile425Leu occurs at a nucleotide that 
was previously identified as a variant and leading to an Ile425Val substitution in two 
families segregating a complex neuropsychiatric phenotype including obsessive-
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compulsive disorder (OCD) and Asperger syndrome.61  Cells expressing Val425 SERT 
exhibit significantly increased surface expression of this protein resulting in elevated 
basal serotonin uptake.47  Val425 encoded SERT does not display altered regulation by 
kinase activation as Gly56 encoded SERT does, but both protein variants do exhibit 
elevated basal serotonin uptake.47, 58  The three newly identified variants in addition to 
Gly56Ala are associated with more severe rigid-compulsive behaviors.58  
 
SLC6A4 Repeat Polymorphisms: HTTPLR and VNTR 
The most commonly studied variants of SLC6A4 are two repeat polymorphisms 
located in noncoding regions of SLC6A4 that affect gene expression.62, 63 The first is a 44 
base pair (bp) insertion/deletion polymorphism (HTTLPR) located 1.2 kb upstream of the 
first exon (1a) that results in a long (l) and a short (s) allele.  
 
        
Figure 3. Schematic representation of HTTLPR.  The 44 bp insertion/deletion 
polymorphism is located approximately 1.2 kb upstream of the first exon of SLC6A4.  
The presence of the 44 bp insertion results in a long allele (l).  Deletion of the 44 bp 
region results in a short allele (s).  The l allele is associated with increased expression of 
SERT. (kb) kilobases, (bp) base pair. 
 
In vitro lymphoblast studies demonstrate the s allele of HTTLPR decreases 
SLC6A4 promoter transcriptional efficiency resulting in a lower concentration of SERT 
5’ 3’ 
EXON 1
~1.2 kb
44 bp insertion 
or deletion 
5 - HTTLPR
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and a reduction in the uptake of serotonin.62  In addition, in vivo imaging studies have 
found a significant increase in raphe SERT levels for l/l homozygous individuals as 
compared to levels in carriers of the s allele.64  
A number of studies have been done looking at association of the s allele with 
various personality traits or preponderance to psychiatric symptoms.  For instance, one 
study found the s allele to be associated with neuroticism.65  Another study found that 
carriers of the s allele have an exacerbated response toward developing depressive 
symptoms as a result of tryptophan depletion regardless of family history of depression; 
although, in heterozygous individuals a family history of depression resulted in an 
increased tendency toward depressive symptoms comparable in degree to homozygous 
carriers of the s allele.66    
 
Association Studies of HTTLPR Polymorphisms with Autism 
Studies looking at association of either HTTLPR allele with autism have been 
largely inconclusive.  Some groups have found positive association of the l allele with 
autism67, 68, some with the s allele with autism,39, 69-71 and a few studies found no 
association of either allele with autism.72-75  Reasons for this discrepancy may be the low 
degree of statistical power resulting from small sample sizes in these studies, the 
difficulty of genotyping this region due to the nature of it being a very GC rich segment, 
and/or differing populations being genotyped and thus differing risk alleles.  Of 
importance, the differing risk alleles would likely be associated with different aspects of 
the autism phenotype, different developmental patterns and/or different traits represented 
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differentially in various autism samples.  In addition, diagnostic criteria and 
ascertainment measures may differ amongst the various groups performing the studies.  
 
VNTR  
The second polymorphism of SLC6A4 is a variable nucleotide tandem repeat 
(VNTR) of a 16-17 bp element located in intron 2 of SLC6A4 (STin2, Serotonin 
Transporter intron 2).  There are typically 9, 10 or 12 repeats of this element commonly 
referred to as STin2.9, STin2.10, STin12, respectively.  VNTR variants demonstrate 
differential expression both in vitro and in vivo.63, 76, 77  Fiskerstrand and colleagues 
performed a study in which they transfected luciferase constructs containing Stin2.10 and 
Stin2.12 (they could not produce a stable construct of STin2.9) into embryonic stem (ES) 
cells and looked at the relative expression differences between the two alleles after 
removing LIF (Leukemia Inhibitory Factor), which is known to keep the cell in an 
undifferentiated state.  STin2.10 increased expression of the luciferase construct by a 
5.77 fold increase, demonstrating an ability of STin2.10 to enhance gene expression of a 
reporter gene.  STin2.12, however, enhanced expression of the reporter gene by a 167.85 
fold increase.76  However, these results do appear to be cell specific as STin2 expression 
constructs do not have observable effects in HeLa cells.76  
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Figure 3.  Schematic representation of the VNTR in SLC6A4.  This polymorphic 
region is located between the second and third exon of SLC6A4.  Depicted are repeats one 
through twelve of the 16-17 bp element and thus a representation of STin2.12.  Removal 
of repeats nine and ten would represent Stin2.10 while removal of repeats six, seven, and 
eight would result in a representation of STin2.9.  STin2.12 is associated with increased 
expression of SERT. This figure is  adapted from Klenova et al. 2004.78 
 
To examine STin2 allelic effects in vivo, the same group performed pronuclear 
injections of expression constructs of Stin2.10 and Stin2.12 variants placed upstream of a 
heterologous promoter driving LacZ into mouse embryos and looked at β-galactosidase 
(βgal) expression in the developing murine brain.  At embryonic day 10.5 (E10.5) βgal 
expression was observed in two regions on either side of the midbrain, neural tube floor 
plate and floor plate of the hindbrain, particularly in rhombomeres four and five for both 
constructs.  However, differential βgal expression patterns were seen in the rostral portion 
of the hindbrain in the regions of rhombomeres one and two; Stin2.10 animals had low 
levels of βgal expression in these rhombomeres whereas those with Stin2.12 had high 
levels of βgal expression in these rhombomeres, comparable to levels of βgal in 
rhombomeres four and five of both variants.63  This study suggests that not only do the 
VNTR polymorphic variants STin2.10 and STin2.12 exhibit differential enhancement 
EXON 2 EXON 3
Repeat    1    2    3    4   5    6     7    8   9   10   11  12
VNTR
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capabilities of reporter gene expression within a given cell type, but may also exhibit 
differential effects on spatial patterns of reporter gene expression.    
 
Association Studies of the Intron 2 VNTR with Autism 
A number of studies testing association of STin2 polymorphisms with autism 
have been undertaken.  Two studies found no preferential transmission of any STin2 
polymorphism with autism.72, 73  A German study also did not find preferential 
transmission of STin2 alleles with autism, but did find evidence for association of a 
haplotype containing the l allele of HTTLPR and STin2.12.67  One early study by the 
Cook laboratory found no preferential transmission of any STin2 polymorphism with 
autism, but did find evidence of significant association of a haplotype containing the s 
allele of HTTLPR and STin2.12.59  Subsequently, this group tested 81 new trios and 
obtained the same results of preferential transmission for a haplotype containing the s 
allele of HTTLPR and STin2.12.74   
One study of 125 Dutch patients with DSM-IV-TR, ADI-R or ADOS 
characterized PDD did not find association between STin2 alleles and PDD, however, 
taking specific autism phentoypes into account by using multivariate analysis to test the 
continuum of behavioral subtypes revealed an association between individuals with the 
homozygous STin2.12 genotype and more severe rigid-compulsive tendencies. Similarly, 
quantitative transmission disequilibrium test (QTDT) analysis revealed an association 
between the STin2.12 allele and more severe rigid-compulsive tendencies.79  The 2006 
study mentioned above by Cook and colleagues tested for association between specific 
autism behavioral subcategories (from ADI-R or ADOS) and STin2 genotype, but found 
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no significant associations.80  Finally, one Irish study of 84 families found excess 
transmission to autistic probands for multiple haplotypes of SLC6A4, the most significant 
being a haplotype defined by three polymorphisms including the STin12 allele.70   
 
Describing the Autism Phenotype 
Lord and colleagues (1994) describe the ADI-R as an effective diagnostic 
measure that is used to determine if behaviors commonly associated with autism or PDDs 
are found in the individual being examined and to evaluate how severe each behavior 
might be.3  This tool is used widely and has been studied extensively to assess and ensure 
its accuracy and relevancy.  It differs from the ADOS in that the primary caregiver of the 
individual who is presenting with these behaviors is interviewed by a trained investigator.  
The assessment is not minor, there are over 100 items on the partially-structured 
diagnostic and a certain threshold must be reached in four key areas for a diagnosis of 
autism to be made: communication, social interaction, repetitive behaviors, and age at 
onset of some symptoms.3, 81  Tadevosyan-Leyfer and colleagues performed a principle 
components analysis of items pertaining to the ADI-R providing a useful set of key 
components characteristic of the autism phenotype.81  These six factors can be used to 
mathematically approximate the nature of an affected individuals phenotype.81  While 
the autism phenotype is described as being comprised of three key features (development 
and use of language, reciprocal social interaction and repetitive behaviors, restricted 
interests and resistance to change in the environment or in daily routines.5) that range in 
severity from person to person, these three categories likely do not accurately represent 
genetically relevant categories.  Thus, the value of a principle components analysis based 
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on a thorough evaluation of the autism phenotype, such as the ADI-R, is the ability to 
parse out a group of components that adequately describe the autism phenotype and 
delineate its features into categories that are likely to be genetically relevant.81  These 
components are: spoken language, social intent, compulsions, developmental milestones, 
savant skills and sensory aversions.81  The first three components, spoken language, 
social intent and compulsions are more closely related to the three categorical features 
used in diagnosing autism.81  Spoken language relates to how well, if at all, an individual 
can produce verbal output, and does not include aspects of language related to individual 
expression of a feeling, idea or desire.81  The second component, social intent, does 
include these aspects of language (including gesturing and greeting) in addition to 
nonverbal communication and ability to relate socially.81  The third component, 
compulsions, reflects the repetitive behaviors, restricted interests and resistance to change 
aspects used to diagnose autism, but does not include motor mannerisms that are complex 
as these characteristics seem to be more related to features of social interaction.81  In fact, 
in a factor analysis study done by Cuccaro and colleagues repetitive sensory motor 
actions was identified as a category distinct from resistance to change.82  The first three 
components in the principle components analysis are necessary for delineating diagnostic 
criteria for autism, but they are not sufficient for a holistic description of the autism 
phenotype.  The second three components, developmental milestones, savant skills and 
sensory aversions, vary from individual to individual to a much greater extent than the 
first three components but are important aspects of the autism phenotype at large and thus 
important to  genetic studies of autism.81      
 
 16
Hypothesis 
 Autism is a highly heritable disorder.  Given the multiple lines of evidence 
supporting serotonergic dysregulation in autism etiology, along with linkage studies 
showing evidence for linkage at the SLC6A4 chromosomal region, I aim to dissect the 
role two repeat polymorphisms of SERT may play in contributing to susceptibility for 
autism.  The goal of my study is to determine if alleles at STin2 and/or HTTLPR 
individually or as haplotypes are associated with autism susceptibility in our sample.  I 
hypothesize that preferential transmission will exist for HTTLPR and VNTR alleles, as 
well as a haplotype of these markers to individuals with autism in our sample. 
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CHAPTER II 
 
MATERIALS AND METHODS 
 
DNA Sample 
The sample for this study consisted of 694 combined multiplex and parent-child 
trio families (see Table 1).  The families were ascertained from multiple sources: 151 
families from the Tufts-Vanderbilt Consortium, 327 from the AGRE Consortium, 131 
from Stanford University and 85 from the University of Iowa.  Within each family is at 
least one proband who demonstrates full ADI criteria for autism and at least one other 
sibling who also met full ADI criteria for autism or presented on the broader spectrum.58  
The ADI or ADI-R were used to assess each affected individual.  In addition, data was 
analyzed based on individualized scores for the six principle components of the autism 
phenotype as based on analysis by Tadevosyan-Leyfer and colleagues.81   
In our ascertainment, subjects that had aberrant karyotypes, a genetic disorder of 
known causation, dysmorphic features or having a diagnosis of Fragile X syndrome were 
not included.  Lymphoblastoid cells, buccal cells or peripheral blood was used to isolate 
DNA from each individual, following the protocol recommended by the Pure Gene 
manufacturer (Gentra Systems, Minneapolis, MN).  
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Table 1. Genotyped families with autism organized by center. Labels are as follows: 
(AGR) Autism Genetics Resource Exchange Consortium, (IOW) Iowa State University 
Medical Center, (STA) Stanford University Medical Center, (TUF) Tufts University 
Medical Center, (VAN) Vanderbilt University Medical Center, (ADI) Autism Diagnostic 
Interview, (ADI-R) Autism Diagnostic Interview-Revised.  Stanford University Medical 
Center used an alternate form of the ADI for which not all questions were available when 
characterizing ascertained subjects. 
 
       
 ALL AGR IOW STA TUF VAN 
Families 694 327 85 131 98 53 
Individuals 2823 1420 361 522 353 167 
Number with autism 1256 623 162 259 153 59 
Female 268 147 26 52 34 9 
Male 988 476 136 207 119 50 
Number without diagnosis 1567 797 199 263 200 108 
Female 814 416 103 139 102 54 
Male 752 381 96 124 98 53 
Number of Families with:   
0 affected 26 15 1 0 9 1 
1 affected 143 36 19 16 27 45 
2 affected 471 244 55 105 60 7 
3 affected 45 29 7 7 2 0 
4 affected 9 3 3 3 0 0 
ADI version ADI / 
ADI-R
ADI ADI* ADI ADI / 
ADI-R 
 
 
 
Determination of Genotype 
Genotypes for HTTLPR were determined using PCR followed by gel-based size 
discrimination of alleles.  Gels were 3% NuSieve (3:1) agarose (FMC Bioproducts; 
Rockland, ME), which allowed for ample discrimination between the longer allele (525 
bp) versus the shorter allele (484 bp).   The following amplifying PCR primers were 
used:  5'-CTGAATGCCAGCACCTAACCCCTAATGT-3' and 
 5'-GGGGAATACTGGTAGGGTGCAAGGAGAA-3.' " 
PCR reaction volumes for HTTLPR were 20 µl, with 40 ng of DNA template and 
0.8 µl of 10 picomolar (pM) primer solution.  The Eppendorf Mastermix 2.5X kit 
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(Eppendorf, North America) supplied the buffer, dNTPS and Taq.  Cycling conditions 
consisted of an initial denaturing step at 95 ºC for three minutes followed by 50 cycles of  
95 ºC for 30 seconds, 61 ºC for 30 seconds, and 72 ºC for one minute.  A final extension 
step was 72 ºC for seven minutes.  
Genotypes for VNTR were also determined using PCR followed by gel-based size 
discrimination of alleles.   Gels were 3.5% NuSieve (3:1) agarose, which allowed for 
clear discrimination between the three STin2 alleles: STin2.12 (390 bp), STin2.10 (360 
bp) and STin2.9 (345 bp).  The following amplifying PCR primers were used: 
Forward: TGGATTTCCTTCTCTCAGTGATTGG and 
Reverse:  TCATGTTCCTAGTCTTACGCCAGTG 
PCR reaction volumes were 20 µl, with 20 ng of DNA template and 0.8 µl of 
10pM primer solution.  The Eppendorf Mastermix 2.5X kit (Eppendorf, North America) 
supplied the buffer, dNTPS and Taq.  Cycling conditions consisted of an initial 
denaturing step at 95 ºC for three minutes followed by 50 cycles of 95 ºC for 30 seconds, 
64 ºC for 30 seconds, and 72 ºC for one minute.  A final extension step was 72 ºC for 
seven minutes.  
 
Statistical Analysis 
 The first step of analyzing the HTTLPR and VNTR data involved quality control 
checks to verify internal controls and to be sure our data was consistent with Mendelian 
inheritance.  In addition, we verified the genotyping efficiency was robust. 
As reviewed by Laird and Lange (2006), the most common and simplest family 
based association test is the transmission disequilibrium test (TDT).83  This test uses trio 
 20
or multiplex families to test whether there is an increased transmission of a given allele or 
alleles to the affected offspring.  In rejecting the null hypothesis that no preferential 
transmission of alleles exists in affected individuals, the marker can be assumed to be in 
linkage disequilibrium (LD) with a disease susceptibility locus (DSL).83  The TDT is 
limited in its use however, particularly with cases of missing parents, complex diseases, 
or cases where the exact allele representation on homologous chromosomes is not 
specified (missing phase).83  An extension of the TDT which allows for testing of 
association despite these factors is the non-parametric family based association tests, or 
FBATs.83, 84  The FBAT is refractory to problems arising due to non-specified complex 
disease models, missing parents, general pedigrees and/or in cases where the distribution 
of a disease in a population is unknown.83, 84  In addition, the FBAT is unaffected by 
population admixture or stratification, and is useful in cases where multiple comparisons 
must be made.83, 84  This test is ideal for studying the association of a given gene in a 
complex disorder, such as the serotonin transporter gene in autism.  
Thus, we used the FBAT84, including the Haplotype Based Association Test 
(HBAT) to determine if any HTTLPR or VNTR alleles or haplotypes of these alleles are 
associated with autism in our sample.  An increased number of permutations results in 
greater analytical precision, thus we performed 1,000 permutations on our sample.  Given 
the gender bias of autism spectrum disorders, we separated our dataset into families 
containing affected males only and families containing affected females only.  
We performed our analysis based on the evidence for linkage driving our dataset 
based on previous findings in our lab.  In addition, we performed a quantitative 
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transmission disequilibrium test  based on the six components key to the autism 
phenotype, as based on the work done by Tadevosyan-Leyfer and colleagues (2003).81   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 22
 
CHAPTER III 
 
RESULTS AND CONCLUSIONS 
 
HTTLPR Results and Discussion 
 
There is no significant association of either HTTLPR allele with autism in our 
sample.  Further, there was no significant association of either HTTLPR allele with 
autism in families with affected males only or in families with affected females only. 
 
Table 2.  FBAT analysis of association of HTTLPR polymorphisms with autism.  
Labels are as follows: (Freq.) allele frequency, (S) seen, (E(S)) Expected to be seen, Var 
(S) variance.  There is no significant association of either HTTLPR allele with autism in 
the total sample, within families with affected males only or within families with affected 
females only.    
 
  
            
P P (-e) P (-p) All Famililes 
0.19 0.22 0.19 
Allele afreq S E(S) Var(S) P 
484 0.458 521 500 281.4 0.22 
528 0.542 517 538 281.4 0.22 
            
P P (-e) P (-p) Affected Males Only  
0.23 0.26 0.22 
Allele afreq S E(S) Var(S) P 
484 0.458 424 407 221.7 0.26 
528 0.542 440 457 221.7 0.26 
            
P P (-e) P (-p) Affected Females Only  
0.59 0.59 0.64 
Allele afreq S E(S) Var(S) P 
484 0.458 131 127 55.6 0.59 
528 0.542 147 151 55.6 0.59 
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These results are consistent with a previous finding of no association between 
HTTLPR genotype and autism,72-75, 85 but disparate with a number of other studies that 
have found association of either the l or s HTTLPR allele with autism.39, 67-71   
As mentioned above, the inconsistency amongst studies of HTTLPR could be due 
to a number of things such as small sample size, difficulty genotyping this region, 
differing family collections possessing somewhat different properties vis-à-vis etiologic 
heterogeneity and thus differing representation of risk alleles.  One very important 
possible reason for the discrepancy among HTTLPR association studies in autism may be 
a failure to account for the effect of a SNP located within the l allele of HTTLPR.     
Ten SNPs have been identified within HTTLPR.86  A prevalent A ! G 
polymorphism located in one of the two additional repeat units of the l allele is associated 
with altered transcriptional efficiency of HTTLPR.87  This makes HTTLPR a tri-allelic 
locus comprised of the s allele and the A and G variants of the l allele, represented as lG 
and lA, respectively.  The lA allele results a 2.8-fold increase in reporter gene expression 
as compared to s allele within transfected RN46A cells.  However, the effect of the lG 
allele on reporter gene expression is equivalent to that of the s allele.87  Further, 
quantitation of SERT mRNA levels in lymphoblastoid cell lines indicates the lA / lA  
genotype results in the highest levels of SERT mRNA while the s/s genotype results in 
the lowest levels of SERT mRNA.87   
The lG allele results in lower transcriptional activity as compared to the lA allele 
due to the corresponding presence of an AP-2 binding site, where AP-2 can suppress 
gene transcription.87  The AP-2 family of transcription factors are important in neural 
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development and AP-2 binding sites are present in regulatory sites in a number of genes 
that are part of monoamine neurotransmitter systems.88  AP-2 acts a suppressor of 
HTTLPR lG and if an oligonucleotide containing the sequence for the lG allele AP2 
binding-site is added into the cell, reporter gene expression between lG and lA will be 
equivalent, indicating that if AP2 fails to bind to its site on the lG allele, transcriptional 
efficiency between both l allele is the same.87   
Xian-Zhang Hu and colleagues studied the frequency of each allele in three 
populations and found the s:lG:lA ratio to be 2.5:5:2.5 in African Americans, 4:5:1 in 
Caucasians, and 2:1:0 in American Indians.87   
Frequently HTTLPR association studies consider this locus to be bi-allelic, not 
taking into account this A!G polymorphism that results in gene expression levels 
equivalent to those of the s allele.  This would presumably result in failure to detect 
possible associations accurately since grouping both l alleles into one group results in a 
dampening effect.87     One large (2,998 total individuals) genotyping study done by Hu 
and colleagues found an s allele frequency of .25 in subjects who were of African 
descent, .35-.40 in Caucasians, and .64-.66 in American Indians, revealing a disparate 
HTTLPR allele frequency among differing populations.87 
In addition, the inconsistency between these studies may partly be explained by 
failure to consider clinical heterogeneity, with which genetic heterogeneity has been 
correlated.  For instance, Cook and colleagues tested the possibility of a genotype-
phenotype interaction by comparing ADI-R and ADOS scores of individuals within the 
different genotype categories of HTTLPR.  Individuals with one or two copies of the s 
allele were found to have higher (more severe) scores on the failure to use nonverbal 
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communication to regulate social interaction subdomain of the ADI-R as compared to 
their l/l counterparts. The l/l individuals tended to have more severe scores on the 
stereotyped and repetitive motor mannerisms subdomain of the ADI-R and also had 
higher ADOS scores on directed facial expressions and unusual sensory interests, 
reflecting the important concept that genotypic heterogeneity often underlies phenotypic 
heterogeneity in complex disorders such as autism.80  This idea is further supported by 
the findings of our lab, which previously observed an increase in the evidence for linkage 
at 17q11.2 at SLC6A4, with the multipoint HLOD score increasing from 2.74 to 3.62 in 
families with more severe rigid-compulsive behaviors.39  In addition, our lab also found 
rare variants in SLC6A4 to be associated with more severe rigid-compulsive behaviors.58  
It is possible that our analysis of HTTLPR did not yield any significant associations 
because we did not test for the lG and lA polymorphisms and because we did not take 
phenotypic heterogeneity into account in this study.  Further analysis to this end is an 
important next step in the study of these data.  
 
VNTR Results 
There is no significant association of any of the VNTR alleles with autism in the 
total sample, within families with affected males only or within families with affected 
females only.  There were only enough individuals in the families with affected females 
only category with the 9 repeat VNTR allele to warrant analysis of this allele.    
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Table 3.  FBAT analysis of association of VNTR polymorphisms with autism.  Labels 
are as follows: (Freq.) allele frequency, (S) seen, (E(S)) Expected to be seen, Var (S) 
variance.  There is no significant association of any of the VNTR alleles with autism in 
the total sample, within families with affected males only or within families with affected 
females only.   
 
            
P P (-e) P (-p) All Families 
0.25 0.28 0.16 
Allele afreq S E(S) Var(S) P 
10 0.358 380 406 284.0 0.12 
12 0.629 692 665 280.9 0.11 
            
P P (-e) P (-p) Affected Male Only 
0.53 0.55 0.42 
Allele afreq S E(S) Var(S) P 
10 0.358 300 315 214.3 0.30 
12 0.629 545 529 214.2 0.28 
            
P P (-e) P (-p) Affected Female Only 
0.38 0.4 0.27 
Allele afreq S E(S) Var(S) P 
9 0.014 7 7 2.8 0.97 
10 0.358 99 110 61.6 0.17 
12 0.629 182 171 63.4 0.18 
 
 
Two previous studies reported no evidence of association at STin2 with autism,72, 
73  two studies reported an association of a haplotype containing the s variant of HTTLPR 
and STin2.12 with autism, 59, 74 and one study found evidence for association of a 
haplotype containing the l variant of HTTLPR and STin2.12 with autism.67  Further, one 
group found excess transmission to autistic probands for multiple haplotypes of SLC6A4, 
the most significant being a haplotype defined by three polymorphisms including the 
STin2.12 allele.70  In addition, two independent groups tested the possibility of 
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association of VNTR polymorphisms with specific autism phenotypes with disparate 
results: Cook and colleagues found no significant association of any STin2 genotype with 
specific behavioral subcategories from ADI-R or ADOS, while Conroy and colleagues 
found an association between individuals with the homozygous STin2.12 genotype and 
more severe rigid-compulsive tendencies. Similarly, QTDT analysis revealed an 
association between the STin2.12 allele and more severe rigid-compulsive tendencies in 
this study.79      
 
 
Discussion of VNTR 
Transcription Factors of VNTR Affecting SERT Expression 
The individual repeat units of STin2 are not all identical in sequence or length.76  
In fact, repeats four, seven, nine, and eleven are only 16 nucleotides in length and there 
are seven unique repeat sequences among the 12 units.76  Only residues 6, 10, 11, 12, 14 
and 15 may be polymorphic, and changes are conservative as only C/T and A/G 
substitutions are observed.76  Unlike trinucleotide repeats which would likely not contain 
enough primary sequence variation to result in multiple transcription factor consensus 
binding motifs, STin2 repeats are relatively large and variable in primary sequence 
information.  These factors increase the probability of transcription factor binding motifs 
that may be specific to a given allele of STin2.     
Y box binding protein (YB-1), a transcription factor, is known to interact with 
STin2.78  In fact, there are 12 potential binding sites within the 12 repeat allele of STin2 
and significantly, these DNA consensus sites span the repeat units of STin2.   
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Figure 5.  Primary sequence of each repeat and location of YB-1 consensus motifs in 
VNTR. Shown are the sequences of each repeat unit of the VNTR in SLC6A4.  The 
sequence is written 5´ to 3´ of the sense strand.  The seven unique sequences among the 
12 repeats are labeled a-g.  Repeats four, seven, nine and eleven are only 16 nucleotides 
in length; all the rest are 17 nucleotides in length.   Highlighted in red are the 12 putative 
binding consensus motifs for YB-1 comprised of the sequences GATG/CATC or 
GGTG/CACC.  These motifs encompass the region of possible sequence variation and 
possible variation in the number of nucleotides per repeat, 16 vs. 17.  Figure taken from 
Klenova et al. 2004.78 
 
The GATG/CATC and GGTG/CACC motifs are consensus motifs recognized and 
bound by YB-1.78, 89  The location of these motifs is important because these sites 
encompass the region of possible sequence variation and possible variation in the number 
of nucleotides per repeat (16 vs. 17 bp).78  Therefore, it is possible that YB-1 may affect 
STin2 expression in a differential pattern based on the primary sequence of the repeat and 
the size of the repeat.  Cotransfection assays in COS7 cells using STin2 variants upstream 
of an SV40 promoter attached to the Luciferase gene (termed pStin2.9Luc, Stin2.10Luc 
and Stin2.12Luc) in addition to a vector containing YB-1, reveal YB-1 differentially 
activates each polymorphism of STin2 in this specific cell line.  PStin2.9Luc expression 
was strongly affected by the presence of YB-1 and an increase in YB-1 concentration 
resulted in increasingly stronger activation of this variant.  On the other hand, the 
pStin2.10Luc expression was not affected by the presence of YB-1 and pStin2.12Luc 
expression was slightly repressed by the presence of YB-1.  This result may partially be 
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cell-specific as pStin2.10Luc was activated by the presence of a relatively low 
concentration of YB-1 in HEK293T cells in addition to pStin2.9Luc being activated by 
YB-1; this lends evidence to the idea that modulation of YB-1s effect on STin2 
expression is affected by factors that may be present in some types of cells and not other 
types.78   
One possible explanation for differential modulation of STin2 variants by YB-1 
could be the frequency of G/A polymorphisms located in the consensus binding motifs in 
STin2.9.  Most of the consensus binding sites located in STin2.12 (the longest STin2 
variant) have the sequence, GGTGGGCT, but two consensus binding sequences, located 
at the junction between repeat six and seven, and at the end of repeat 12 have the 
sequence GATGGGCT.  The use of the GGTGGGCT consensus sequence between 
repeat three and four (rep 3/4) along with the GATGGGCT consensus sequence (rep 6/7) 
in EMSA competition experiments with a specific inhibitor oligonucleotide and YB-1, 
demonstrates differential binding of YB-1 to each type of motif.  Specifically, rep 3/4 
(GGTGGGCT) formed four complexes with YB-1 and only two of these complexes 
could be outcompeted by the presence of the inhibitor oligonucleotide, however, rep 6/7 
(GATGGGCT) formed two complexes with YB-1 (with a faint third complex 
occasionally being observed) and all complexes could be outcompeted by the inhibitor 
oligonucleotide, although it did take more oligonucleotide to produce this effect than it 
did for the two complexes that dissociated in rep 3/4.78  This suggests differential binding 
of YB-1 to GATTGGGCT motifs vs. GGTGGGCT motifs; the oligonucleotide with the 
GGTTGGGCT motif (rep 3/4) formed more (four total) complexes with YB-1 proteins 
and only two of them could be outcompeted by the inhibitor oligonucleotide.  
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Conversely, the GATGGGCT oligonucleotide motif only formed two to three complexes 
with YB-1 and all complexes could be outcompeted (although with more inhibitor 
nucleotide than it took to out-compete the two GGTTGGGCT motif complexes).   
One study done by Lovejoy and colleagues further supports the hypothesis that 
STin2 repeat domains differ in their ability to regulate enhancement of reporter gene 
expression.77  This group used ES cells to study the enhancement capabilities of each 
individual repeat, and also that of two larger oligonucleotides that span two separate 
repeat units.77   
 
Figure 6.  Sequence of the “spanning” oligonucleotides of VNTR tested for reporter 
gene expression enhancement in ES cells.  The sequence of each repeat is written 5 to 
3 along the sense strand.  The seven unique sequences among the 12 repeats are labeled 
a-g.  Underlined are the two spanning oligonucleotides tested for enhancing ability in 
an expression assay. The spanning c/d oligonucleotide has the sequence 
GACCCGGGGTGGGCTGT while the spanning f/d oligonucleotide has sequence, 
GACCTGGGATGGGCTGT.  (RP) repeat.  This figure was taken from Lovejoy et. al. 
2003.77   
 
 Figure 5 shows the seven unique repeat sequences tested in addition to two 
spanning oligonucleotides (termed c/d and f/d) that were also tested for enhancer 
activity.  The spanning c/d oligonucleotide has the sequence 
GACCCGGGGTGGGCTGT while the spanning f/d oligonucleotide has sequence, 
 31
GACCTGGGATGGGCTGT.  Repeat units c and g showed a small-fold increase in 
enhancer activity upon removal of LIF, whereas repeat unit e did not show a significant 
increase in enhancer activity.77  Surprisingly, the f/d oligonucleotide construct supported 
a 4.1 fold increase and the c/d construct supported a 13.5 fold increase in enhancer 
activity even though these two constructs differ by just two nucleotide residues.77  Thus, 
it appears that sequence variation, not just repeat number, of the STin2 repeat 
polymorphism, is an important determinant in enhancer ability, at least in murine ES 
cells.77  Interestingly, when these oligonucleotides are tested in the human placental cell 
line, JAR (often used to test SLC6A4 promoter function) the results are quite different 
with there not being a significant difference in the enhancing ability of the c repeat vs. the 
c/d repeat.77  The researchers in this study conclude that transcription factors that may 
bind to the differing transcription factor motifs within the VNTR domain are activated by 
tissue specific stimuli, not ubiquitous non-specific stimuli like that which would bind to a 
constitutively active regulatory domain.77  
 
CTCF: Interaction with YB-1 for Regulation of STin2 
The implications for the differential binding properties of the two types of YB-1 
consensus motifs in STin2 are further amplified when factors modulating YB-1s 
interaction with STin2 are taken into account.  One example of a factor that affects the 
effect of YB-1 on STin2 polymorphisms is CCTC-binding protein (CTCF).78  CTCF has 
an 11-zinc finger DNA-binding domain and can bind to very divergent DNA sequences 
of approx. 50 bp in length within the promoter regions of human c-myc genes (reviewed 
in reference 72).90  Baculoviral-produced CTCF is able to cause dissociation of YB-1 -
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STin2.12 complexes as well as YB-1rep 3/4 and YB-1rep 6/7 complexes.78  In 
addition, co-transfection studies reveal that CTCF results in a strong inhibition of STin2.9 
expression in COS7 and HEK 293T cells, but only when YB-1 is present.78  In fact, in the 
absence of YB-1, CTCF has no effect on the expression levels of any of the STin2 
polymorphisms in COS7 or HEK 293T cells.78  PStin2.10Luc expression is increased by 
the presence of YB-1 in HEK 293T cells but when CTCF is added, the increase in 
expression is not as substantial.78  These experiments indicate that CTCF negatively 
regulates the enhancement effects of YB-1 on STin2 expression.  The investigators 
suggest that this regulation could occur through either of two distinct mechanisms: first, 
CTCF could bind to the YB-1 consensus motif on STin2, resulting in stereotaxic 
inhibition of this region for activation by YB-1.  Alternatively, CTCF might bind to YB-
1, resulting in the loss of YB-1s ability to bind to its recognition motif on STin2.  The 
latter postulation is likely based on studies revealing that CTCF binds to YB-1 through 
interaction of CTCFs zinc-finger region with YB-1.90  Truncation interaction studies 
reveal that YB-1 binds to the zinc-finger region of CTCF through YB-1s DNA-binding 
cold-shock domain (CSD) located on the N-terminal.78  Finally, if CTCF was exerting its 
inhibitory effect through stereotaxic inhibition of YB-1s recognition motif, one would 
expect a CTCF-STin2 complex present in the EMSA studies mentioned above and this 
was not observed.78  
 
Possible Reasons for Differential Expression 
To summarize, YB-1 differentially regulates STin2 polymorphisms in vitro and 
this is dependent upon cell type.  In addition, at least one factor that we know of, CTCF, 
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can diminish the enhancement effects of YB-1 on STin2 expression for those variants of 
STin2 that are responsive to YB-1.  The question that arises, is, why is there such a 
drastic difference in how each STin2 polymorphism is affected by YB-1?  
Although observed STin2 alleles are highly similar, differences exist that may 
have far-reaching implications for effects on expression.  The effects of YB-1 may 
depend on the secondary structure of the DNA to which it is binding.78, 89  Thus, we must 
consider the possibility that differences in both repeat number and complement (i.e. the 
number of 16 bp vs. 17 bp repeats and the presence of C/T or G/A variants) for STin2 
may affect the binding of YB-1 (and possibly many other transcription factors) through 
secondary structure effects on the DNA of this region.  Repeats six, seven, and eight are 
absent from the STin2.9 allele, and repeats nine and ten are absent in STin2.10.78  This 
means that one of the two GATGGGCT motifs (rep 6/7) is not present in STin2.9.  Based 
on the strength of STin2.9 activation by YB-1 in vitro, it is possible that when the rep 6/7 
motif is bound by YB-1 in STin2.10 or STin2.12, it may diminish enhancement of STin2 
expression by YB-1, perhaps through secondary DNA structure effects.78, 89  In addition, 
the presence of a single nucleotide polymorphism (within STin2.10 and STin2.12; G/A) 
at two locations, can affect how strongly YB-1 may bind, but also likely produces new 
transcription factor binding motifs recognized by entirely different transcription factors 
and indeed, this is the case.78  In fact, the presence of the G/A polymorphism in repeat six 
results in the creation of a number of predicted transcription factor binding sites for such 
transcription factors as TCF11/KCR-F1/Nrf1 homodimers, activator protein-1 and 
retinoic acid receptor-related orphan receptor alpha 1.78  STin2.9 would only carry one 
GATGGCT motif and thus would only contain one binding site for these other 
 34
transcription factors unlike STin2.10 and STin2.12 which would each have two binding 
sites for these factors.  However data are not yet available showing that any of the 
predicted factors functionally act on these sequences. Also unaddressed in this study was 
a discussion of why observable differences exist between the enhancing capabilities of 
STin2.10 and STin2.12, not just differences between STin2.9 and both STin2.10 and 
STin2.12.  Unlike STin2.9, differential frequency of G/A polymorphisms would not 
likely be a possible explanation for differential regulatory abilities of STin2.10 vs. 
STin2.12, since both alleles have the two G/A polymorphisms present.  One possible 
explanation for the difference in enhancing capacities is the size difference in the alleles, 
and thus the likely alteration in secondary DNA structure.  At this point, however, no 
further assumptions can be made without additional expression and transcription factor 
binding studies. 
STin2.12 is known to enhance reporter gene expression in ES cells by a 167 fold 
increase as compared to STin2.10 which enhanced reporter gene expression by only 5-6 
fold.76  Thus one possible effect of this polymorphism is enhanced expression of 
SLC6A4.  We know that depending on the cell type, the various repeats of STin2 and the 
various polymorphisms seem to have independent regulatory effects on reporter gene 
transcription.  Thus, while there is evidence for differential enhancer properties of the 
individual variants even within a given cell type, we must also consider the enhancer 
profile of each variant depending upon cell type. Different complements of transcription 
factors exist in differing cell types and the various STin2 polymorphisms may be affected 
differently. Recall that STin2 variants produced differential expression patterns in the 
brain of developing mouse embryos: Stin2.10 embyros had low levels of reporter-gene 
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expression in the region of rhombomeres one and two whereas Stin2.12 embryos had 
high levels of reporter-gene expression in these rhombomeres, comparable to levels of 
reporter-gene in rhombomeres four and five of both variants.63  This rostral portion of the 
hindbrain expresses SLC6A4 mRNA and is involved in the formation of serotonergic cell 
clusters.63  Thus, one could speculate that having one or more copies of the STin2.12 
allele could result in higher expression of SLC6A4 anywhere SLC6A4 is expressed, but 
could also, and perhaps more importantly, result in a significantly different spatial profile 
of SERT in the brain of a given individual.  Given the differences between the male and 
female brain anatomy, this differential spatial profile may be an important factor to 
consider in light of a possible STin2.12 gender bias.   
While Stin2, or VNTR, plays a role in the expression of SLC6A4, it may not play 
enough of a role to be associated with a complex neuropsychiatric disorder such as 
autism.   
 
Haplotype Analysis Results 
There was no significant association of a haplotype containing specific alleles of 
HTTLPR or VNTR with autism in our sample.   A haplotype containing the s allele of 
HTTLPR and STin2.12 has been previously associated with autism in two separate 
studies,59, 74 and one study found association of the l allele of HTTLPR and STin2.12 in 
autism.67   
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Table 4.  Haplotype Based Association Test for association of an 
HTTLP/VNTR haplotype with autism.  There was no significant association of a 
haplotype containing specific alleles of HTTLPR or VNTR with autism in our sample 
  
            
P P (-e) P (-p) All Families 
0.11 0.17 0.07 
            
P P (-e) P (-p) Affected Male Only 
0.16 0.25 0.12 
            
P P (-e) P (-p) Affected Female Only 
0.41 0.44 0.35 
 
The results of our analysis make sense since there was no significant association 
of any of the HTTLPR or VNTR alleles with autism in our sample.  
 
Quantitative Transmission Disequilibrium Test Results 
Finally, we performed a quantitative transmission disequilibrium test based on the 
six components key to the autism phenotype.81  There were no significant associations of 
HTTLPR or VNTR alleles with any of the six components in the combined dataset.  
Maternal inheritance of HTTLPR or VNTR alleles was not significantly associated with 
any of the six components.  However, paternal inheritance of VNTR alleles was 
associated with two components, the social intent component and the milestones 
component (p = .02 and p = .05, respectively).   
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Table 5.  QTDT analysis for parental transmission of HTTLPR and VNTR alleles.  
There were no significant associations of HTTLPR or VNTR alleles with any of the six 
components in the combined dataset.  Maternal inheritance of HTTLPR or VNTR alleles 
was not significantly associated with any of the six components.  However, paternal 
inheritance of VNTR alleles was associated with two components, the social intent 
component and the milestones component (p = .02 and p = .05, respectively).   
 
              
OVERALL Language_t Social Milestones_t Savant_t Rigid_t Sensory_t 
VNTR 0.90 0.40 0.70 1.00 0.90 0.50 
HTTLPR 0.90 0.30 0.50 0.60 0.10 0.90 
              
Maternal 
Only Language_t Social Milestones_t Savant_t Rigid_t Sensory_t 
VNTR 0.600 0.500 0.100 0.400 0.100 0.700 
HTTLPR 0.500 0.600 0.300 0.200 0.400 0.700 
              
Paternal Only Language_t Social Milestones_t Savant_t Rigid_t Sensory_t 
VNTR 0.700 0.020 0.050 0.900 0.400 0.600 
HTTLPR 0.800 0.400 0.700 0.300 0.400 0.300 
 
The social intent component is related to individual expression of a idea, desire or 
feeling and includes gesturing and greeting in addition to nonverbal communication and 
ability to relate socially.81  The milestones component relates to the attainment of 
milestones in physical and mental development.81   
Given the lack of association for any HTTLPR or VNTR alleles with autism, we 
have to consider the possibility that these two association results could be due to chance.  
This would seem most likely for the milestones component as it is nominally significant. 
Further study needs to be done to determine if paternal inheritance of VNTR alleles 
contributes to susceptibility for autism.   
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